Last Updated : April 22, 2025
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
efanesoctocog alfa (Altuviiio)
Therapeutic Area: congenital factor VIII deficiency
Draft recommendations posted for stakeholder feedback: April 17, 2025
End of feedback period: May 5, 2025
Draft Recommendation
rozanolixizumab (Rystiggo)
Therapeutic Area: Generalized myasthenia gravis (gMG)
Draft recommendations posted for stakeholder feedback: April 17, 2025
End of feedback period: May 5, 2025
Draft Recommendation
ruxolitinib (Opzelura)
Therapeutic Area: Nonsegmental vitiligo
Draft recommendations posted for stakeholder feedback: April 17, 2025
End of feedback period: May 5, 2025
Draft Recommendation
trofinetide (Daybue)
Therapeutic Area: Rett syndrome (RTT)
Draft recommendations posted for stakeholder feedback: April 17, 2025
End of feedback period: May 5, 2025
Draft Recommendation
dabrafenib-trametinib (TBC)
Therapeutic Area: Pediatric low grade glioma (ped LGG)
Draft recommendations posted for stakeholder feedback: April 11, 2025
End of feedback period: April 29, 2025
Draft Recommendation
Draft Responses to the Questions from the Drug Programs
Draft Clinical & Pharmacoeconomic Combined Report
Draft Combined Report Supplemental Material
regorafenib (N/A)
Therapeutic Area: Metastatic osteosarcoma
Draft recommendations posted for stakeholder feedback: April 11, 2025
End of feedback period: April 29, 2025
Draft Recommendation
Draft Responses to the Questions from the Drug Programs
Draft Clinical & Pharmacoeconomic Combined Report
Draft Combined Report Supplemental Material
Dabrafenib trametinib(N/A)
Therapeutic Area: Head and neck cancer
Draft recommendations posted for stakeholder feedback: April 11, 2025
End of feedback period: April 29, 2025
Draft Recommendation
Draft Responses to the Questions from the Drug Programs
Draft Clinical & Pharmacoeconomic Combined Report
Draft Combined Report Supplemental Material
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area :
recurrent or metastatic nasopharyngeal carcinoma
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
primary biliary cholangitis
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Chronic inflammatory demyelinating polyneuropathy
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Unresectable or advanced hepatocellular carcinoma (HCC)
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
atopic dermatitis
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
HER2-low or HER2-ultralow breast cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Giant cell arteritis
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Immunoglobulin G4-related disease
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Astrocytoma or oligodendroglioma; IDH1 or IDH2 mutation
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :